Abstract

IntroductionBreast cancer is the most common malignant tumor in women worldwide. However, advanced multidisciplinary therapy cannot rescue the mortality of high-risk breast cancer metastasis. Ferroptosis is a newly discovered form of regulating cell death that related to cancer treatment, especially in eradicating aggressive malignancies that are resistant to traditional therapies. However, the prognostic value of ferroptosis-related gene in breast cancer remains unknown.Materials and MethodsIn this study, a total of 1,057 breast cancer RNA expression data with clinical and follow-up information were downloaded from the TCGA cohort, multivariate Cox regression was used to construct the 11-gene prognostic ferroptosis-related gene signature. The breast cancer patients from the GEO cohort were used for validation. The expression levels of core prognostic genes were also verified in erastin-treated breast cancer cell lines by real-time polymerase chain action (PCR).Results and DiscussionOur results showed that 78% ferroptosis-related genes were differentially expressed between breast cancer tumor tissue and adjacent non-tumorous tissues, including 29 of them which were significantly correlated with OS in the univariate Cox regression analysis. Patients were divided into high-risk group and low-risk group by the 11-gene signature. Patients with high-risk scores had a higher probability of death earlier than the low-risk group both in the TCGA construction cohort and in the GEO validation cohort (all P < 0.001). Meanwhile, the risk score was proved to be an independent predictor for OS in both univariate and multivariate Cox regression analyses (HR > 1, P < 0.01). The predictive efficacy of the prognostic signature for OS was further verified by the time-dependent ROC curves. Moreover, we also enriched many immune-related biological processes in later functional analysis; the immune status showed a statistical difference between the two risk groups. In addition, the differences in expression levels of 11 core prognostic genes were examined in ferroptosis inducer-treated breast cancer cell lines.ConclusionIn conclusion, a novel ferroptosis-related gene model can be used for prognostic prediction in breast cancer. New ferroptosis-related genes may be used for breast cancer targeting therapy in the future.

Highlights

  • Breast cancer is the most common malignant tumor in women worldwide

  • After the identification of prognostic ferroptosis-related differentially expressed genes (DEGs) in the The Cancer Genome Atlas (TCGA) cohort, results showed that most of the ferroptosis-related genes (202/259, 78%) were differentially expressed between breast cancer tumor tissues and adjacent non-tumorous tissues, including 29 of them which were significantly correlated with overall survival (OS) in the univariate Cox regression analysis (Figure 2A)

  • A total of 29 prognostic ferroptosis-related DEGs were identified by the criteria of false discovery rate (FDR) < 0.05 (Figures 2B,C)

Read more

Summary

Introduction

Breast cancer is the most common malignant tumor in women worldwide. Breast cancer is the most common malignant tumor in women worldwide; among 70–80% patients with early, non-metastatic disease can be cured. Under the joint multidisciplinary diagnosis and treatment model of surgery, radiotherapy, chemotherapy, endocrinology, and targeted precision therapy, the mortality of advanced breast cancer or high-risk breast cancer with metastasis has not been significantly improved (Emens, 2018). All these data highlight the additional need for innovative methods to identify patients with high-risk disease

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call